Teplizumab, a Type 1 diabetes immunotherapy drug, has been proven to slow onset of the disease by 2 years. This landmark discovery could lead to potential reduction in long-term health risks related to diabetes. Find out how the drug works and who might benefit in this week’s MedBlog. Learn more.
November 6, 2019